GOG-0241
Complete
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #113912) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Principal Investigator
David Gershenson
Status
Complete
Temporarily Closed to Accrual
October 28, 2013
Closed to Accrual
October 28, 2013
Closed to Accrual & Treatment
October 28, 2013
Closed to Accrual & Treatment
July 11, 2014
Complete
April 15, 2019
Disease Site
Gynecologic [GY] Ovarian
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if capecitabine and oxaliplatin reduces the death rate compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.
To determine if bevacizumab reduces the death rate compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.
Patient Population
Women with mucinous adenocarcinoma of the ovary or fallopian tube.
Target Accrual
60
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
